{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:46:16Z","timestamp":1789757176833,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["PO1 DCA 168585"],"award-info":[{"award-number":["PO1 DCA 168585"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011360","name":"Office of Research, Health Sciences, University of Pittsburgh","doi-asserted-by":"publisher","award":["T32"],"award-info":[{"award-number":["T32"]}],"id":[{"id":"10.13039\/100011360","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SPORE Pittsburgh","award":["P50 CA121973-03"],"award-info":[{"award-number":["P50 CA121973-03"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA191234-01A1"],"award-info":[{"award-number":["1R01CA191234-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joy and Jerry Monkarsh","award":["1"],"award-info":[{"award-number":["1"]}]},{"name":"Vincent Price Research Fund","award":["1"],"award-info":[{"award-number":["1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-1862-y","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T09:02:51Z","timestamp":1554454971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interleukin 32 expression in human melanoma"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-1185","authenticated-orcid":false,"given":"Helicia","family":"Paz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Kalbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6rthe","family":"Schaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena M.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Graeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Economou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"issue":"2","key":"1862_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cyto.2012.07.010","volume":"60","author":"B Heinhuis","year":"2012","unstructured":"Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012;60(2):321\u20137.","journal-title":"Cytokine"},{"issue":"20","key":"1862_CR2","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1007\/s00018-013-1301-9","volume":"70","author":"LA Joosten","year":"2013","unstructured":"Joosten LA, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Cell Mol Life Sci. 2013;70(20):3883\u201392.","journal-title":"Cell Mol Life Sci"},{"key":"1862_CR3","doi-asserted-by":"publisher","first-page":"8413768","DOI":"10.1155\/2016\/8413768","volume":"2016","author":"MB Khawar","year":"2016","unstructured":"Khawar MB, Abbasi MH, Sheikh N. IL-32: a novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediat Inflamm. 2016;2016:8413768.","journal-title":"Mediat Inflamm"},{"issue":"1","key":"1862_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3892\/ol.2014.2641","volume":"9","author":"S Wang","year":"2015","unstructured":"Wang S, Chen F, Tang L. IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett. 2015;9(1):305\u20137.","journal-title":"Oncol Lett."},{"issue":"2","key":"1862_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1354750X.2016.1252956","volume":"22","author":"Y Wang","year":"2017","unstructured":"Wang Y, Yang Y, Zhu Y, Li L, Chen F, Zhang L. Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer. Biomarkers. 2017;22(2):165\u201370.","journal-title":"Biomarkers"},{"key":"1862_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12957-015-0552-3","volume":"13","author":"Y Yang","year":"2015","unstructured":"Yang Y, Wang Z, Zhou Y, Wang X, Xiang J, Chen Z. Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol. 2015;13:146.","journal-title":"World J Surg Oncol."},{"issue":"30","key":"1862_CR7","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1038\/onc.2011.52","volume":"30","author":"JH Oh","year":"2011","unstructured":"Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, et al. IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene. 2011;30(30):3345\u201359.","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"1862_CR8","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1002\/mc.21990","volume":"53","author":"ES Park","year":"2014","unstructured":"Park ES, Yoo JM, Yoo HS, Yoon DY, Yun YP, Hong J. IL-32gamma enhances TNF-alpha-induced cell death in colon cancer. Mol Carcinog. 2014;53(Suppl 1):E23\u201335.","journal-title":"Mol Carcinog"},{"issue":"11","key":"1862_CR9","doi-asserted-by":"publisher","first-page":"9061","DOI":"10.18632\/oncotarget.3197","volume":"6","author":"HM Yun","year":"2015","unstructured":"Yun HM, Park KR, Kim EC, Han SB, Yoon DY, Hong JT. IL-32alpha suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget. 2015;6(11):9061\u201372.","journal-title":"Oncotarget."},{"issue":"26","key":"1862_CR10","doi-asserted-by":"publisher","first-page":"17868","DOI":"10.1074\/jbc.M900368200","volume":"284","author":"A Nishida","year":"2009","unstructured":"Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem. 2009;284(26):17868\u201376.","journal-title":"J Biol Chem"},{"issue":"7","key":"1862_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/carcin\/bgt092","volume":"34","author":"TS Plantinga","year":"2013","unstructured":"Plantinga TS, Costantini I, Heinhuis B, Huijbers A, Semango G, Kusters B, et al. A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma. Carcinogenesis. 2013;34(7):1529\u201335.","journal-title":"Carcinogenesis"},{"issue":"2","key":"1862_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/carcin\/bgv172","volume":"37","author":"B Heinhuis","year":"2016","unstructured":"Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 2016;37(2):197\u2013205.","journal-title":"Carcinogenesis"},{"issue":"4","key":"1862_CR13","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.4049\/jimmunol.1601477","volume":"199","author":"L Gorvel","year":"2017","unstructured":"Gorvel L, Korenfeld D, Tung T, Klechevsky E. Dendritic cell-derived IL-32alpha: a novel inhibitory cytokine of NK cell function. J Immunol. 2017;199(4):1290\u2013300.","journal-title":"J Immunol."},{"issue":"14","key":"1862_CR14","doi-asserted-by":"publisher","first-page":"12049","DOI":"10.1074\/jbc.M110.159756","volume":"286","author":"S Cheon","year":"2011","unstructured":"Cheon S, Lee JH, Park S, Bang SI, Lee WJ, Yoon DY, et al. Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. J Biol Chem. 2011;286(14):12049\u201355.","journal-title":"J Biol Chem"},{"issue":"1","key":"1862_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2567.2011.03513.x","volume":"135","author":"MH Park","year":"2012","unstructured":"Park MH, Song MJ, Cho MC, Moon DC, Yoon DY, Han SB, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012;135(1):63\u201372.","journal-title":"Immunology"},{"issue":"1","key":"1862_CR16","first-page":"131","volume":"22","author":"SH Kim","year":"2005","unstructured":"Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22(1):131\u201342.","journal-title":"Immunity"},{"issue":"6","key":"1862_CR17","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar2074","volume":"8","author":"H Shoda","year":"2006","unstructured":"Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006;8(6):R166.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"1862_CR18","doi-asserted-by":"publisher","first-page":"e1985","DOI":"10.1371\/journal.pone.0001985","volume":"3","author":"W Li","year":"2008","unstructured":"Li W, Liu Y, Mukhtar MM, Gong R, Pan Y, Rasool ST, et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE. 2008;3(4):e1985.","journal-title":"PLoS ONE"},{"issue":"9","key":"1862_CR19","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1073\/pnas.0712381105","volume":"105","author":"MG Netea","year":"2008","unstructured":"Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA. 2008;105(9):3515\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1862_CR20","doi-asserted-by":"publisher","first-page":"e1181237","DOI":"10.1080\/2162402X.2016.1181237","volume":"6","author":"H Ohmatsu","year":"2017","unstructured":"Ohmatsu H, Humme D, Gonzalez J, Gulati N, Mobs M, Sterry W, et al. IL-32 induces indoleamine 2,3-dioxygenase(+)CD1c(+) dendritic cells and indoleamine 2,3-dioxygenase(+)CD163(+) macrophages: relevance to mycosis fungoides progression. Oncoimmunology. 2017;6(2):e1181237.","journal-title":"Oncoimmunology."},{"issue":"5","key":"1862_CR21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/jid.2013.488","volume":"134","author":"H Suga","year":"2014","unstructured":"Suga H, Sugaya M, Miyagaki T, Kawaguchi M, Fujita H, Asano Y, et al. The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134(5):1428\u201335.","journal-title":"J Invest Dermatol."},{"issue":"40","key":"1862_CR22","doi-asserted-by":"crossref","first-page":"65825","DOI":"10.18632\/oncotarget.11669","volume":"7","author":"J Lee","year":"2016","unstructured":"Lee J, Kim KE, Cheon S, Song JH, Houh Y, Kim TS, et al. Interleukin-32alpha induces migration of human melanoma cells through downregulation of E-cadherin. Oncotarget. 2016;7(40):65825\u201336.","journal-title":"Oncotarget."},{"issue":"17","key":"1862_CR23","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","volume":"21","author":"JM Taube","year":"2015","unstructured":"Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969\u201376.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1862_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","volume":"4","author":"DJ Konieczkowski","year":"2014","unstructured":"Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816\u201327.","journal-title":"Cancer Discov"},{"key":"1862_CR25","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun."},{"issue":"5","key":"1862_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33(5):890\u2013904.","journal-title":"Cancer Cell."},{"issue":"7420","key":"1862_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136.","journal-title":"Nature"},{"issue":"12","key":"1862_CR28","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","volume":"4","author":"M Uhlen","year":"2005","unstructured":"Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom. 2005;4(12):1920\u201332.","journal-title":"Mol Cell Proteom"},{"key":"1862_CR29","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1126\/science.aan2507","volume":"357","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:6352.","journal-title":"Science."},{"issue":"5","key":"1862_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"269","key":"1862_CR31","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal."},{"issue":"8","key":"1862_CR32","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","volume":"8","author":"A Mehta","year":"2018","unstructured":"Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 2018;8(8):935\u201343.","journal-title":"Cancer Discov"},{"issue":"6","key":"1862_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst."},{"issue":"1","key":"1862_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cell.2007.05.042","volume":"130","author":"MG Guenther","year":"2007","unstructured":"Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007;130(1):77\u201388.","journal-title":"Cell"},{"issue":"11","key":"1862_CR35","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.15252\/embr.201540945","volume":"16","author":"T Zhang","year":"2015","unstructured":"Zhang T, Cooper S, Brockdorff N. The interplay of histone modifications\u2014writers that read. EMBO Rep. 2015;16(11):1467\u201381.","journal-title":"EMBO Rep"},{"issue":"1","key":"1862_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrg2905","volume":"12","author":"VW Zhou","year":"2011","unstructured":"Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet. 2011;12(1):7\u201318.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"1862_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.molcel.2017.10.013","volume":"68","author":"LM Soares","year":"2017","unstructured":"Soares LM, He PC, Chun Y, Suh H, Kim T, Buratowski S. Determinants of histone H3K4 methylation patterns. Mol Cell. 2017;68(4):773\u201385.","journal-title":"Mol Cell."},{"issue":"2","key":"1862_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/pcmr.12348","volume":"28","author":"Y Qin","year":"2015","unstructured":"Qin Y, Milton DR, Oba J, Ding Z, Lizee G, Ekmekcioglu S, et al. Inflammatory IL-1beta-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res. 2015;28(2):236\u20139.","journal-title":"Pigment Cell Melanoma Res."},{"issue":"8","key":"1862_CR39","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1074\/jbc.M111.288290","volume":"287","author":"B Heinhuis","year":"2012","unstructured":"Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA. Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012;287(8):5733\u201343.","journal-title":"J Biol Chem"},{"issue":"9","key":"1862_CR40","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1073\/pnas.0511206103","volume":"103","author":"D Novick","year":"2006","unstructured":"Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA. 2006;103(9):3316\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1862_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2567.2008.02917.x","volume":"126","author":"JD Choi","year":"2009","unstructured":"Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, et al. Identification of the most active interleukin-32 isoform. Immunology. 2009;126(4):535\u201342.","journal-title":"Immunology"},{"issue":"16","key":"1862_CR42","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1073\/pnas.1424302112","volume":"112","author":"X Bai","year":"2015","unstructured":"Bai X, Shang S, Henao-Tamayo M, Basaraba RJ, Ovrutsky AR, Matsuda JL, et al. Human IL-32 expression protects mice against a hypervirulent strain of Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2015;112(16):5111\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1862_CR43","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4014\/jmb.1404.04012","volume":"24","author":"SJ Kim","year":"2014","unstructured":"Kim SJ, Lee S, Kwak A, Kim E, Jo S, Bae S, et al. Interleukin-32gamma transgenic mice resist LPS-mediated septic shock. J Microbiol Biotechnol. 2014;24(8):1133\u201342.","journal-title":"J Microbiol Biotechnol"},{"issue":"9","key":"1862_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/cgt.2011.37","volume":"18","author":"Y Qu","year":"2011","unstructured":"Qu Y, Taylor JL, Bose A, Storkus WJ. Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther. 2011;18(9):663\u201373.","journal-title":"Cancer Gene Ther"},{"key":"1862_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40001-015-0083-y","volume":"20","author":"B Khawar","year":"2015","unstructured":"Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation. Eur J Med Res. 2015;20:7.","journal-title":"Eur J Med Res."},{"issue":"38","key":"1862_CR46","doi-asserted-by":"publisher","first-page":"40747","DOI":"10.18632\/oncotarget.5688","volume":"6","author":"MS Kim","year":"2015","unstructured":"Kim MS, Kang JW, Jeon JS, Kim JK, Kim JW, Hong J, et al. IL-32theta gene expression in acute myeloid leukemia suppresses TNF-alpha production. Oncotarget. 2015;6(38):40747\u201361.","journal-title":"Oncotarget."},{"issue":"42","key":"1862_CR47","doi-asserted-by":"publisher","first-page":"35556","DOI":"10.1074\/jbc.M112.400911","volume":"287","author":"JW Kang","year":"2012","unstructured":"Kang JW, Park YS, Lee DH, Kim JH, Kim MS, Bak Y, et al. Intracellular interaction of interleukin (IL)-32alpha with protein kinase Cepsilon (PKCepsilon) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells. J Biol Chem. 2012;287(42):35556\u201364.","journal-title":"J Biol Chem"},{"issue":"2","key":"1862_CR48","doi-asserted-by":"publisher","first-page":"e0005413","DOI":"10.1371\/journal.pntd.0005413","volume":"11","author":"JC Dos Santos","year":"2017","unstructured":"Dos Santos JC, Heinhuis B, Gomes RS, Damen MS, Real F, Mortara RA, et al. Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species. PLoS Negl Trop Dis. 2017;11(2):e0005413.","journal-title":"PLoS Negl Trop Dis."},{"issue":"250","key":"1862_CR49","doi-asserted-by":"publisher","first-page":"250ra114","DOI":"10.1126\/scitranslmed.3009546","volume":"6","author":"D Montoya","year":"2014","unstructured":"Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. Sci Transl Med. 2014;6(250):250ra114.","journal-title":"Sci Transl Med."},{"issue":"4","key":"1862_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.2650","volume":"18","author":"M Schenk","year":"2012","unstructured":"Schenk M, Krutzik SR, Sieling PA, Lee DJ, Teles RM, Ochoa MT, et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med. 2012;18(4):555\u201363.","journal-title":"Nat Med"},{"issue":"6","key":"1862_CR51","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3390\/v7062762","volume":"7","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Zhu Y. Important role of the IL-32 inflammatory network in the host response against viral infection. Viruses. 2015;7(6):3116\u201329.","journal-title":"Viruses."},{"issue":"2","key":"1862_CR52","doi-asserted-by":"publisher","first-page":"e1701729","DOI":"10.1126\/sciadv.1701729","volume":"4","author":"RJ Palstra","year":"2018","unstructured":"Palstra RJ, de Crignis E, Roling MD, van Staveren T, Kan TW, van Ijcken W, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Sci Adv. 2018;4(2):e1701729.","journal-title":"Sci Adv."},{"issue":"4","key":"1862_CR53","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jso.24142","volume":"113","author":"MB Nicholl","year":"2016","unstructured":"Nicholl MB, Chen X, Qin C, Bai Q, Zhu Z, Davis MR, et al. IL-32alpha has differential effects on proliferation and apoptosis of human melanoma cell lines. J Surg Oncol. 2016;113(4):364\u20139.","journal-title":"J Surg Oncol"},{"key":"1862_CR54","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1038\/cddis.2013.166","volume":"4","author":"HM Yun","year":"2013","unstructured":"Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, et al. Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. Cell Death Dis. 2013;4:e640.","journal-title":"Cell Death Dis."},{"issue":"12","key":"1862_CR55","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1073\/pnas.1016005108","volume":"108","author":"B Heinhuis","year":"2011","unstructured":"Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LA. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci USA. 2011;108(12):4962\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1862_CR56","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","volume":"72","author":"ML Hartman","year":"2015","unstructured":"Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci. 2015;72(7):1249\u201360.","journal-title":"Cell Mol Life Sci"},{"key":"1862_CR57","doi-asserted-by":"publisher","first-page":"730170","DOI":"10.1155\/2011\/730170","volume":"2011","author":"I Yajima","year":"2011","unstructured":"Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Iida M, et al. Molecular network associated with MITF in skin melanoma development and progression. J Skin Cancer. 2011;2011:730170.","journal-title":"J Skin Cancer."},{"key":"1862_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.abb.2014.07.019","volume":"563","author":"JJ Hsiao","year":"2014","unstructured":"Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys. 2014;563:28\u201334.","journal-title":"Arch Biochem Biophys"},{"key":"1862_CR59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fonc.2018.00173","volume":"8","author":"F Ahmed","year":"2018","unstructured":"Ahmed F, Haass NK. Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance. Front Oncol. 2018;8:173.","journal-title":"Front Oncol."},{"issue":"3","key":"1862_CR60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cyto.2009.03.007","volume":"46","author":"H Kobayashi","year":"2009","unstructured":"Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine. 2009;46(3):351\u20138.","journal-title":"Cytokine"},{"issue":"1A","key":"1862_CR61","first-page":"61","volume":"22","author":"I Lugowska","year":"2018","unstructured":"Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn). 2018;22(1A):61\u20137.","journal-title":"Contemp Oncol (Pozn)."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-1862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-1862-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-1862-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T09:07:02Z","timestamp":1589533622000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-1862-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1862"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-1862-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"113"}}